Eli Lilly and Company Website

Eli Lilly and Company

NYSE-LLY

Basic

  • Market Cap

    $815.4B

  • EV

    $838.48B

  • Shares Out

    900.41M

  • Revenue

    $35.93B

  • Employees

    43,000

Margins

  • Gross

    80.16%

  • EBITDA

    37.22%

  • Operating

    32.86%

  • Pre-Tax

    21.04%

  • Net

    17.08%

  • FCF

    -0.25%

Returns (5Yr Avg)

  • ROA

    13.52%

  • ROTA

    -603.61%

  • ROE

    94.37%

  • ROCE

    24.48%

  • ROIC

    20.12%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $901.48

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $2,652.5M

  • Net Debt

    $22.99B

  • Debt/Equity

    2.04

  • EBIT/Interest

    20.98

Growth (CAGR)

  • Rev 3Yr

    12.13%

  • Rev 5Yr

    10.69%

  • Rev 10Yr

    4.94%

  • Dil EPS 3Yr

    0.55%

  • Dil EPS 5Yr

    1.99%

  • Dil EPS 10Yr

    6.62%

  • Rev Fwd 2Yr

    24.38%

  • EBITDA Fwd 2Yr

    60.89%

  • EPS Fwd 2Yr

    73.83%

  • EPS LT Growth Est

    40.6%

Dividends

  • Yield

  • Payout

    68.77%

  • DPS

    $4.69

  • DPS Growth 3Yr

    15.17%

  • DPS Growth 5Yr

    14.99%

  • DPS Growth 10Yr

    9.12%

  • DPS Growth Fwd 2Yr

    15.15%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

22,319.5

24,539.8

28,318.4

28,541.4

34,124.1

35,932.1

Total Revenues % Chg.

3.8%

9.9%

15.4%

0.8%

19.6%

29.8%

Cost of Goods Sold, Total

4,721.2

5,483.3

6,973.1

6,629.8

7,082.2

7,129

Gross Profit

17,598.3

19,056.5

21,345.3

21,911.6

27,041.9

28,803.1

Selling General & Admin Expenses, Total

6,003.9

5,869.4

6,141.9

6,067.5

6,941.2

7,143.9

R&D Expenses

5,595

5,976.3

6,930.7

7,190.8

9,313.4

9,851.1

Other Operating Expenses, Total

11,598.9

11,845.7

13,072.6

13,258.3

16,254.6

16,995

Operating Income

5,999.4

7,210.8

8,272.7

8,653.3

10,787.3

11,808.1

Interest Expense, Total

-400.6

-359.6

-339.8

-331.6

-485.9

-562.7

Interest And Investment Income

80.4

33

25.4

62.8

173.6

185.2

Net Interest Expenses

-320.2

-326.6

-314.4

-268.8

-312.3

-377.5

Currency Exchange Gains (Loss)

-61.9

123.7

-204.6

-191.3

-26.4

-26.4

Other Non Operating Income (Expenses)

5.3

-319.2

256

177

-6.3

20.3

EBT, Excl. Unusual Items

5,622.6

6,688.7

8,009.7

8,370.2

10,442.3

11,424.5

Restructuring Charges

-77.8

-151.2

-13

-23

-45.5

-45.5

Merger & Related Restructuring Charges

-400.7

Gain (Loss) On Sale Of Investments

401.2

1,442.2

176.9

-410.7

-20.2

9.5

Gain (Loss) On Sale Of Assets

309.8

Asset Writedown

In Process R&D Expenses

-239.6

-769.8

-970.1

-908.5

-3,799.8

-3,805.3

Other Unusual Items

-349.6

20

-1,048

-221.6

-22.2

-22.2

EBT, Incl. Unusual Items

5,265.9

7,229.9

6,155.5

6,806.4

6,554.6

7,561

Income Tax Expense

628

1,036.2

573.8

561.6

1,314.2

1,422.6

Earnings From Continuing Operations

4,637.9

6,193.7

5,581.7

6,244.8

5,240.4

6,138.4

Earnings Of Discontinued Operations

3,680.5

Net Income

8,318.4

6,193.7

5,581.7

6,244.8

5,240.4

6,138.4

Net Income to Common Incl Extra Items

8,318.4

6,193.7

5,581.7

6,244.8

5,240.4

6,138.4

Net Income to Common Excl. Extra Items

4,637.9

6,193.7

5,581.7

6,244.8

5,240.4

6,138.4

Total Shares Outstanding

907.5

906.6

903.7

900.2

899.4

900.4

Weighted Avg. Shares Outstanding

931.1

907.6

907

901.7

900.2

900.1

Weighted Avg. Shares Outstanding Dil

935.7

912.5

911.7

904.6

903.3

903.4

EPS

8.9

6.8

6.2

6.9

5.8

6.8

EPS Diluted

8.9

6.8

6.1

6.9

5.8

6.8

EBITDA

7,232

8,534.7

9,820.3

10,175.8

12,314.6

13,373.7

Effective Tax Rate

11.9%

14.3%

9.3%

8.3%

20.1%

18.8%